Latest Content

10 of 3515 Shown
  • A Focus on AML: Applying the Latest Research to Individualize Therapy

    If you attended the AML Satellite Symposium on December 2nd in San Diego but were unable to complete the evaluation form, please download it here.
    Date Posted: 12/5/2016
  • Learning Module

    Metastatic Non-Small-Cell Lung Cancer

    Leora Horn, MD, MSc, FRCPC, provides a comprehensive look at current optimal therapy for patients with metastatic NSCLC.
    Faculty: Leora Horn MD, MSc, FRCPC
    Released: 12/2/2016
  • Preview of ASH 2016: Top Expert-Selected Studies

    John M. Burke MD - 12/1/2016
    Look for these important studies at the coming Hematology meeting in San Diego. Be sure to also check our Web site frequently for downloadable PowerPoint slides featuring key presented data.
  • Immune Checkpoint Inhibitors: A New Hope for Patients With Merkel Cell Carcinoma

    Sandra P. D'Angelo MD - 11/30/2016
    In this commentary, Sandra P. D’Angelo, MD, highlights the practice-changing use of immune checkpoint inhibitor therapy for the treatment of patients with metastatic Merkel cell carcinoma.
  • Clinical Dilemma: A Patient With a Diagnosis of Stage IV NSCLC-NOS Is Referred to You for a Second Opinion

    Leora Horn MD, MSc, FRCPC - 11/21/2016 2 comments / Last Comment: 11/28/2016
    In the age of targeted therapies and immune checkpoint inhibition, Leora Horn, MD, MSc, FRCPC, discusses the importance of avoiding diagnoses of lung cancer–not otherwise specified in the optimal treatment of patients with newly diagnosed, advanced NSCLC.
  • Learning Module cme-icon

    IDO Inhibitors in Cancer Immunotherapy

    In this CME-certified module, Geoffrey T. Gibney, MD, discusses promising research showing benefit to IDO inhibition approaches in early-phase studies in melanoma, lung cancer, and other cancers.
    Faculty: Geoffrey T. Gibney MD
    Released: 11/16/2016
  • IDO Inhibitors in Cancer Immunotherapy

    In this downloadable slideset, Geoffrey T. Gibney, MD, discusses key clinical and preclinical developments in the use of IDO inhibitors in cancer immunotherapy.
    Date Posted: 11/16/2016
  • Should You Use IgHV Mutation Status to Select Optimal Choice of Therapy for Your Patients With CLL?

    Jeff P. Sharman MD - 11/16/2016
    How I incorporate IgHV mutations status in my current clinical practice.
  • Clinical Development of Immune Checkpoint Inhibitors in HCC

    In this downloadable slideset, Ghassan K. Abou-Alfa, MD, MBA, reviews the rationale for immunotherapy in hepatocellular carcinoma, as well as the emerging and ongoing data supporting the use of immune checkpoint inhibitors to treat patients with HCC, from a satellite symposium at the 2016 American Association for the Study of Liver Diseases Annual Meeting.
    Date Posted: 11/14/2016
  • New Hope for Elderly Patients With AML: A Sneak Peek at ASH 2016

    B. Douglas Smith MD - 11/14/2016
    Treating elderly patients with AML is particularly challenging. The upcoming ASH conference will include presentations from numerous studies of novel approaches that promise to improve outcomes for these patients.
10 of 3515 Shown
Show 10 More
Decision Support
Immediate answers to treatment questions
More than just up to date